High cancer drug prices in the United States: Reasons and proposed solutions

Journal of Oncology Practice

Volumn 10, Issue 4, 2013, Pages e208-e211

  Kantarjian, Hagop ^a   Steensma, David ^a   Sanjuan, Judit Rius ^a   Elshaug, Adam ^a   Light, Donald ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; DRUG COST; HEALTH CARE SYSTEM; INCOME; MORALITY; REVIEW; UNITED STATES; ECONOMICS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; NEOPLASMS; PHYSICIAN ATTITUDE;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; DRUG COSTS; HEALTH CARE REFORM; HEALTH EXPENDITURES; HUMANS; NEOPLASMS; PHYSICIAN'S ROLE; UNITED STATES;

EID: 84923068857     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2013.001351     Document Type: Review

References (34)

1. Kantarjian HM, Foto T, Mathisen M, et al: Cancer drugs in the United States: Justum pretium - the just price. J Clin Oncol 28:3006-4, 2013
2. Light DW, Kantarjian H: Market spiral pricing of cancer drugs. Cancer 119:3900-3902, 2013
3. Kantarjian H, Experts in chronic myelogenous leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 121: 4439-4442, 2013
4. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014
5. Light DW, Warburton R: Demythologizing the high costs of pharmaceutical research. BioSocieties 1745-8552:1-17, 2011
6. Huff EA: Big pharma lies about R&D costs to justify illicit profits. www.naturalnews.com/031657-BigPharma-drug-development-costs.html
7. st-century cancer drug pricing. J Clin Oncol 27:2111-2113, 2009
8. Stiglitz J: The Price of Inequality. New York, NY, W.W. Norton, 2012, p 45
9. Scherer FM: The F.T.C., Oligopoly, and Shared Monopoly. Faculty Research Working Paper Series. Harvard Kennedy School. September 2013. https://research.hks.harvard.edu/publications/getFile.aspx?Id=978
10. Light DW: Basic research funds to discover important new drugs: Who contributes how much? in Burke MA, ed: Monitoring the Financial Flows for Health Research 2005: Behind the Global Numbers. Geneva, Switzerland, Global Forum for Health Research, 2006, pp 27-43
11. Light DW, Lexchin J: Foreign free riders and the high price of US medicines. BMJ: 331:958-960, 2005
12. Wyatt E: Justices to take up generic drug case. New York Times, December 8, 2012:B1
13. Das K, Petigara T, Anderson G: Price negotiations for drugs in the U.S. Health Policy Monitor, April 2007. www.hpm.org/survey/us/b9/3
14. Rome E: Big pharma CEOs rake in $1.57 billion in pay. Huff Post Business. www.huffingtonpost.com/ethan-rome/big-pharma-ceo-pay-b-3236641.html
15. Rome E: Big pharma pockets $711 billion in profits by robbing seniors, taxpayer. Huff Post Politics. www.huffingtonpost.com/ethan-rome/big-pharma-pockets-711-bi-b-3034525.html
16. Baker D: The savings from an efficient Medicare prescription drug plan. www.cepr.net/documents/efficient-medicare-2006-01.pdf
17. Patient Centered Outcome Research Institute. www.pcori.org/about-us/governance-and-leadership/
18. US Food and Drug Administration: For industry: Importations of drugs. www.fda.gov/Forindustry/importProgram/ucm173751.htm
19. The Center for Public Integrity: Opinion: Big pharma's stranglehold on Washington. www.publicintegrity.org/2013/02/11/12175/opinion-big-pharmas-stranglehold-washington
20. Rosenthal E: The soaring cost of a simple breath. The New York Times http://www.nytimes.com/2013/10/13/us/the-soaring-cost-of-a-simple-breath.html?-r=0&hp=&adxnnl=1&pagewanted=print&adxnnlx=1382023735-oq0uw+jCp8un3cLsW4GCRw
21. Center for Responsive Politics: Lobbying spending database pharmaceuticals/health products, 2012. www.opensecrets.org/lobby/indusclient.php?id=H04&year=2012
22. Pinheiro CP: Drug donations: What lies beneath. Bulletin of the World Health Organization. www.who.int/bulletin/volumes/86/8/07-048546/en/
23. Hillstrom S: Charitable donations of drugs by corporations. www.drugdonations.org
24. Business Wire: Patient assistance scam-AIDS drug company "charity" programs fail patients, yet provide millions in tax breaks to industry, says AHF. www.businesswire.com/news/home/20110802007295/en/Patient-Assistance-Scam-AIDS-Drug-Company
25. Guilloux A, Moon S: Hidden price tags: Disease-specific drug donations: Costs and alternatives. www.deolhonaspatentes.org.br/media/file/publicacoes/hidden-price-tags.pdf
26. Fein, AJ: How hospitals inflate specialty drug prices. Drug Channels. www.drugchannels.net/2012/10/how-hospitals-inflate-specialty-drug.html
27. NICE: http://www.nice.org.uk/
28. Berry SR, Bell CM, Ubel PA, et al: Continental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Onc 28:4149-4153, 2010
29. Ginsburg JA, Kline M, Doherty RB: How can our nation conserve and distribute health care resources effectively and efficiently? American College of Physicians. www.acponline.org/advocacy/where-we-stand/policy/health-care-resources.pdf
30. Dickson M, Hurst J, Jacobzone S: Survey of pharmacoeconomic assessment activity in eleven countries. Organization for Economic Cooperationand Development. www.oeed.org/dataoecd/27/25/2955828.pdf
31. Lopert R, Elshaug A: Australia's 'fourth hurdle' drug review comparing costs and benefits holds lessons for the United States. Health Aff (Millwood) 32:78-87, 2013
32. The Act on the Reform on the Market for Medicinal Products (Gesetz zur Neuordnung des Arzneimittelmarktes-AMNOG). www.bmg.bund.de/ministerium/english-version/amnog.html
33. Anonymous. German pharma criticizes new AMNOG vetting procedure. The Pharma Letter. March 2012. www.thepharmaletter.com/file/111771/german-pharma-criticizes-new-amnog-vetting-procedure.html.
34. Hogerzeil HV: Big pharma and social responsibility - The Access to Medicine Index. N Engl J Med 369:896, 2013